IFW

Case Docket No. VFORGE.006C1

Date: June 25, 2004



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Takruri, H.

Appl. No.

10/698,320

Filed

October 31, 2003

For

PIRENZEPINE OPHTHALMIC

**GEL** 

Examiner

Unknown

Group Art Unit:

1615

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop: Amendment,, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 25, 2004

1/1/1

Nancy W. Vensko, Reg. No. 36,298

## TRANSMITTAL LETTER

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with fifteen (15) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Nancy W. Vensko Registration No. 36,298 Attorney of Record Customer No. 20,995

(805) 547-5580

Docket No.: VFORGE.006C1

## INFORMATION DISCLOSURE STATEMENT

Applicant

Takruri, H.

App. No.

: 10/698,320

Filed

: October 31, 2003

For

PIRENZEPINE OPHTHALMIC GEL

Examiner

Unknown

Group Art Unit

1615

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 15 references. Copies of disclosed U.S. patents and/or publications are not included pursuant to PTO waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for applications filed after June 30, 2003. Copies of other references, if listed, are enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

6/25/04

B<sub>v</sub>:

Nancy W. Vensko

Registration No. 36,298

Attorney of Record

Customer No. 20,995

(805) 547-5580

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VFORGE.006C1	APPLICATION NO. 10/698,320
JUN 2 8 7004 8	DISCLOSURE STATEMENT APPLICANT	APPLICANT Takruri, H.	
(USE SEVERAL	SHEETS IF NECESSARY)	FILING DATE October 31, 2003	GROUP 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	US 5,055,302	10/08/1991	Laties et al.			
	2	US 5,122,522	06/16/1992	Laties et al.			
	3	US 5,284,843	02/08/1994	Stone et al.			
	4	US 5,356,892	10/18/1994	Laties et al.			
	5	US 5,360,801	11/01/1994	Laties et al.			
	6	US 5,385,939	01/31/1995	Laties et al.			
	7	US 5,461,052	10/24/1995	Stone et al.			
	8	US 5,516,808	05/14/1996	Sawaya A.S.			
	9	US 5,567,731	10/22/1996	Laties et al.			
	10	US 5,571,823	11/05/1996	Stone et al.			
	11	US 5,637,604	06/10/1997	Laties et al.			
	12	US 5,888,493	03/30/1999	Sawaya A.S.			

FOREIGN PATENT DOCUMENTS								
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION
INITIAL		,			1		YES	NO
	13	WO 01/52832	07/26/2001	PCT			., -	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)				
	14	Stone. R.A. et al. 1991 "Muscarinic antagonist effects on experimental chick myopia" Exp. Eye Res. 52: 755-758.			
	15	Tigges, M. et al. 1999 "Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys" <i>Optom. Vis. Sci.</i> <b>76</b> :397-407.			

O:\DOCS\MXG\MXG-5161.DOC 051404

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WIT	